SCHEMBL5510799

SCHEMBL5510799

O=C1N=C(NCc2cccs2)S/C1=C\Cc1ccc2nccc(Cl)c2c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 13/20 0.38
DYRK1A Q13627 5/20 0.38
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 6/20 0.35
LMNA P02545 6/20 0.35
CYP1A2 P05177 6/20 0.35
CYP3A4 P08684 6/20 0.35
CYP2D6 P10635 6/20 0.35
CYP2C19 P33261 6/20 0.35
TSHR P16473 4/20 0.35
MAPK1 P28482 3/20 0.35
EGFR P00533 1/20 0.35
PTPN1 P18031 1/20 0.35
PTPN11 Q06124 1/20 0.35
USP2 O75604 4/20 0.35
CLK1 P49759 2/20 0.35
HIF1A Q16665 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
HSD17B10 Q99714 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503592 0.88 CLK4 (0.42) CLK4DYRK1AALDH1A1LMNACYP1A2
SCHEMBL5502564 0.86 CLK4 (0.38) CLK4DYRK1AALDH1A1LMNACYP1A2
SCHEMBL14437203 0.85 CDK1 (0.40) CLK4DYRK1ANPC1ALDH1A1LMNA
SCHEMBL5505043 0.85 CLK4 (0.36) CLK4DYRK1ANPC1ALDH1A1LMNA
SCHEMBL5507768 0.84 CLK4 (0.36) CLK4DYRK1AALDH1A1LMNACYP1A2
SCHEMBL5509527 0.83 ALDH1A1 (0.41) CLK4DYRK1ANPC1ALDH1A1LMNA
SCHEMBL5507148 0.82 CCNB2 (0.38) CLK4DYRK1ANPC1ALDH1A1LMNA
SCHEMBL5517255 0.76 EGFR (0.35) EGFR
SCHEMBL5505196 0.75 SLC2A1 (0.36) NPC1ALDH1A1LMNATSHRMAPK1
SCHEMBL5508501 0.73 ABL1 (0.33) CYP3A4POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7253285-B2 Thiazolinone 4-monosubstituted quinolines HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US claimed
EP-1797085-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. Hoffmann-Roche AG (CH) 2007-06-20 EP claimed
US-20060063805-A1 Thiazolinone 4-monosubstituted quinolines CHEN LI 2006-03-23 US claimed
WO-2006029861-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 WO claimed
US-7253285-B2 Thiazolinone 4-monosubstituted quinolines HOFFMANN-LA ROCHE INC. (US) 2007-08-07 US disclosed
EP-1797085-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. Hoffmann-Roche AG (CH) 2007-06-20 EP disclosed
US-20060063805-A1 Thiazolinone 4-monosubstituted quinolines CHEN LI 2006-03-23 US disclosed
WO-2006029861-A1 THIAZOLINONE 4-MONOSUBSTITUTED QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2006-03-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060063805-A1 Thiazolinone 4-monosubstituted quinolines CDK1, CDK14, CDK17 CLK4 327/4885DYRK1A 571/4885NPC1 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.